Encoded Therapeutics secures $275M Series F to advance gene therapy for Dravet syndrome

Encoded Therapeutics announced a $275 million Series F financing round aimed at moving its lead gene‑therapy candidate, ETX101, toward pivotal trials for Dravet syndrome.

In the ongoing Phase 1/2 POLARIS study, a single dose of ETX101 produced a median 79 % reduction in monthly countable seizures for three patients and an 89 % reduction for five patients after one year, alongside reported improvements in cognitive and adaptive behavior.

The company said the new capital will fund the pivotal trial in infants and young children and expand the program to treat children up to 18 years old, with the goal of delivering a disease‑modifying, one‑time therapy for patients with SCN1A mutations.